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Abstract
Background: Laparoscopic hysterectomy (LH) for the treatment of early-stage endometrial carcinoma/cancer (EC)
has demonstrated to be safe in several randomized controlled trials. Yet, data on implementation of LH in clinical
practice are limited. In the present study, implementation of LH for EC was evaluated in a large oncology network
in the Netherlands.
Results: Retrospectively, a total of 556 EC patients with FIGO stage I-II were registered in the selected years. The
proportion of LH gradually increased from 11% in 2006 to 85% in 2015. LH was more often performed in patients
with low-grade EC and was not related to the studied patient characteristics. The introduction of TLH was
frequently preceded by LAVH. Patients treated in teaching hospitals were more likely to undergo a LH compared to
patients in non-teaching hospitals. The conversion rate was 7.7%, and the overall complication rates between LH
and AH were comparable, but less postoperative complications in LH.
Conclusions: Implementation of laparoscopic hysterectomy for early-stage EC increased from 11 to 85% in
10 years. Implementation of TLH was often preceded by LAVH and was faster in teaching hospitals.
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Background
Endometrial carcinoma/cancer (EC) is the most common
malignancy of the female genital tract, with an increasing
incidence in western countries [1]. In the Netherlands,
about 1900 women are diagnosed with EC yearly. Due to
the fact that most patients are diagnosed at an early stage,
outcome is relatively favorable. However, 400 women die
of this disease annually in the Netherlands [2]. Primary
treatment consists of a total hysterectomy and bilateral
salpingo-oophorectomy. Routine lymphadenectomy is not
beneficial in early-stage, low-risk EC [3]. Historically,
hysterectomy for EC was performed by laparotomy. In
1989, Harry Reich performed the first laparoscopic hys-
terectomy (LH) for a benign gynecological disease [4].
Subsequently, LH became an alternative approach for
abdominal surgery with the advantage of an increased
recovery time and reduced blood loss [5]. In 2006, the
results from the Laparoscopic Approach to Carcinoma
of the Endometrium (LACE) trial, a randomized con-
trolled trial (RCT) including 509 patients with stage I
EC, were published. This study demonstrated a similar
survival in patients treated by total laparoscopic hyster-
ectomy (TLH) compared to those who underwent
abdominal hysterectomy (AH). The benefits of a lap-
aroscopic approach included shorter hospital stay, less
analgesics, and reduced perioperative morbidity [6].
These data were confirmed by a Dutch RCT including
283 patients with stage I EC, who were also randomized
between TLH and AH [7]. The benefits of a laparo-
scopic approach seem to be even more relevant in
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obese patients with an increased risk of surgical mor-
bidity [8]. This is particularly relevant in EC, as obesity
is an important risk factor for the development of EC
[9]. Yet, especially in morbidly obese patients, laparo-
scopic surgery for EC requires a well-trained team, with
a completed learning curve of the surgeon, and anes-
thesiologists that are used to steep Trendelenburg pos-
ition during surgery [10]. Over the last decades, the
percentage of LH as a primary surgical treatment in EC
has increased [11]. Factors that might influence the
adoption of LH in clinical practice have been reported
to be related to age and sex of the gynecologist and the
presence of gynecology residents [12–14].
Previous studies have focused on the implementation
of laparoscopy in general gynecology in the Netherlands
and have shown a slowly increase of LH from 3% in
2007 to 10% in 2012 [15]. However, these data are based
on questionnaires sent to gynecologists about their per-
formed surgeries. So far, only a few studies have focused
on the implementation of LH in the surgical treatment
of EC. In a recent study, out of 5239 hysterectomies for
EC in the USA, 51% was performed by laparoscopy in
2012 [16]. Bogani et al. demonstrated in a single-center
study the implementation of laparoscopic surgery in the
management of all types of gynecological cancers and
showed an increase from 10 to 82% in a 10-year time
period [17]. The aim of the present study was to
evaluate the implementation of LH in the treatment of
early-stage EC over the past 10 years in a large clinical
oncology network and to determine which patient-,
hospital-, and surgeon-related factors contributed to
the implementation of LH. In addition, we evaluated
the conversion and complication rates as well as the
duration of laparoscopic surgery in relation to the
annual number of EC surgeries per hospital.
Methods
Setting
A retrospective cohort study was performed in the
Gynecological Oncology Centre South (GOCS), a clinical
oncology network in the south of the Netherlands. The
GOCS comprises eight collaborating hospitals: two
oncological referral centers, four teaching hospitals,
and two non-teaching hospitals. According to Dutch
guidelines, surgical staging and lymph node dissection
in clinical stage I, endometrioid-type EC are recom-
mended only in case of clinical suspicion of lymph node
metastasis or in case of high-grade histology, i.e., grade 3
endometrioid-type and all non-endometrioid-type EC
cases. Adjuvant therapy consists of radiotherapy by either
external beam radiation or vaginal vault brachytherapy,
depending on the patient’s age, myometrial invasion, LVSI,
and tumor grade on final pathology [18, 19].
Patients
All patients that underwent primary surgical treatment
for EC in 2006, 2009, 2012, or 2015 within the GOCS
were included. Patients planned for a hysterectomy for
another reason (n = 13), e.g., uterine myomas, but were
diagnosed postoperatively with EC, were documented,
but were excluded for analysis since the planned surgery
was not based on the preoperative diagnosis of EC.
Patients that received neoadjuvant chemotherapy, radio-
therapy, or hormonal therapy were excluded (n = 5), as
well as patients that were diagnosed with other uterine
tumors (n = 10). Patients were classified according to the
2009 International Federation of Gynecology and Ob-
stetrics (FIGO) staging system [20, 21]. Routine pre-
operative work-up in the Netherlands consists of a chest
X-ray for low-risk (grade 1–2) endometrioid-type EC,
and computed tomography scan for high-risk tumors,
and only in low-grade EC when there is clinical suspi-
cion of extended disease. Determination of myometrial
invasion is not routinely performed (www.oncoline.nl).
Data extraction
Patient and tumor characteristics were extracted from
patient files, pathology reports, and anesthesiological
screenings. The following patient characteristics were
collected: body mass index (BMI), comorbidity, previous
surgery, and smoking habit. Both the planned and the
performed surgical approaches were registered. LH was
categorized into TLH and laparoscopic-assisted vaginal
hysterectomy (LAVH). TLH was defined as a complete
laparoscopic surgical approach including closure of the
vaginal vault. When part of the procedure was done
vaginally, including closure of the vaginal vault, it was
recorded as LAVH. For patients that were planned for a
laparoscopic approach but underwent AH, the reason
for conversion was documented according to the follow-
ing factors: adhesions, limited exposure, anesthesiological
difficulties due to Trendelenburg position, and uncon-
trolled bleeding. In addition, complications during surgery
and postoperatively were documented.
Outcome
Primary outcome was defined as the percentage of lap-
aroscopic hysterectomies in all patients with FIGO stage
I–II EC in 2006, 2009, 2012, and 2015, compared to the
percentage of abdominal hysterectomies. Secondary out-
comes were the determination of predictive factors for a
laparoscopic approach and the relation between annual
surgical volume and duration of surgery. Predictive fac-
tors for the laparoscopic approach were classified as
patient, hospital, and surgeon related (age and gender).
The type of hospital was classified as teaching and non-
teaching hospital. Surgeon-related factors were age and
gender of the surgeon. The duration of the surgical
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procedures (LH and AH) was related to the annual num-
ber of patients undergoing surgery for EC within the
hospitals.
Statistical analysis
Descriptive analyses were used to describe patients treated
with LH and AH. Differences in characteristics between
patients treated with LH and AH were assessed using Stu-
dent’s t tests for continuous variables and the chi-square
test for categorical data. A multivariable logistic regression
was performed to determine the association of the follow-
ing patient-, hospital-, and surgeon-related factors with the
likelihood of a laparoscopic hysterectomy: age of the
patient, previous abdominal surgery, BMI, and diabetes
mellitus. Patients who could potentially receive either LH
or AH were included, i.e., those treated in 2012 and 2015,
since LH was implemented in most hospitals in these years
and those patients with a grade I and stage I and II endo-
metrial cancer [11]. Statistical analyses were conducted
using IBM SPSS Statistics, version 20 (SPSS Inc., Chicago,
IL, USA). p values < 0.05 were considered statistically
significant, and all statistical tests were two-sided.
Results
Patient cohort
A total of 662 patients were diagnosed with EC within
the selected years: 2006, 2009, 2012, and 2015. Twenty-
eight patients were excluded due to other tumor types
(n = 10), neoadjuvant chemotherapy (n = 5), and unex-
pected EC (n = 13). Subsequently, for analysis, only
patients with FIGO stage I–II EC were included, result-
ing in 556 eligible patients, as demonstrated in Fig. 1.
Patient and tumor characteristics are demonstrated in
Table 1. There were no differences between patients that
underwent a LH or AH with respect to age, BMI, parity,
smoking, or duration of surgery. There were 19 conver-
sions to laparotomy (7.7%): 14 due to adhesions, two
due to uncontrolled bleeding, two due to anesthesiologi-
cal difficulties, and one due to limited exposure. The
conversions were different over time: 2006 (25.0%), 2009
(3.3%), 2012 (10.0%), and 2015 (6.9%). Previous abdom-
inal surgery was not a risk factor for conversion to lapar-
otomy (p = 0.722). Although there was no difference in
the overall complication rate between LH and AH, peri-
operative complications were observed more frequently
in the LH group, whereas postoperative complications
were observed more frequently in the AH group.
Complications during surgery in the AH group con-
sisted of the following: intestinal wall injury (n = 3),
bleeding (n = 3), and damage to the obturator nerve
(n= 1). Complications in the LH group consisted of the fol-
lowing: intestinal wall injury (n= 10), bleeding (n= 4), injury
to the bladder (n= 2), rupture of the cervix (n = 2), and
uterine rupture (n = 1). Postoperative complications in the
Fig. 1 Flow chart of the patient inclusion and surgical procedures
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AH group consisted of wound dehiscence (n = 18), urinary
tract infection (n = 3), wound infection (n = 2), and post-
operative bleeding (n = 1). Complications after surgery in
the LH group consisted of wound infection (n = 4), urinary
tract infection (n = 1), and wound dehiscence (n = 1).
Surgical procedure during the years
During the study period, a steady rise of both LAVH
and TLH was demonstrated, as illustrated in Fig. 2. In
2006, only eight (11%) patients underwent surgery by
the laparoscopic approach, compared to 30 (19.7%) in
2009, 93 (60%) in 2012, and 117 (85%) in 2015. One
teaching hospital introduced the laparoscopic approach
for the treatment of EC in 2006. The remaining teaching
hospitals started performing laparoscopic surgery be-
tween 2006 and 2015. The two non-teaching hospitals
initiated LH for EC between 2012 and 2015. In five
hospitals, the introduction of LAVH preceded the imple-
mentation of TLH.
Predictors of laparoscopic hysterectomy
There was no relation between patient-related factors,
such as BMI (OR 1.00, 95% CI 0.98–1.0), previous ab-
dominal surgery (OR 1.06, 95% CI 0.89–1.26), age (OR
0.98, 95% CI 0.97–1.00), type II DM (OR 0.59, 95% CI
0.34–1.02), and hypertension (OR 1.00, 95% CI 0.66–
1.50) with the type of surgical approach. In addition,
there was no relation between surgeon-related factors
and type of surgery. Patients that underwent surgery in
teaching hospitals were more likely to be operated by a lap-
aroscopic approach compared to non-teaching hospitals
(OR 4.65, 95% CI 2.59–8.36).
Duration of surgery
For all hospitals, the mean duration of surgery was cal-
culated for LH and AH and related to the number of EC
patients operated annually. As illustrated in Fig. 3, the
mean duration of AH was independent of the number of
performed procedures. Yet, for the duration of LH, there
was a trend towards a longer operating time when less
EC patients were treated per year.
Discussion
This study showed an imposing increase in laparoscopic
treatment of early-stage EC from 11% of the procedures
in 2006 to 85% in 2015, reflecting that LH was well
implemented in the past decade in the studied clinical
oncology network in the Netherlands. The introduction
of TLH was frequently preceded by LAVH. The only
predictive factor for a laparoscopic approach was treat-
ment in a teaching hospital.
To the best of our knowledge, this is the first study
that reports upon the implementation of LH in the treat-
ment of EC over a 10-year period since the publication
of the LACE trial in 2006. In a recently published study,
results over a 4-year time span demonstrated an increase
in minimally invasive hysterectomy of 22% in 2007 to
51% in 2011 in the USA [22]. Data are in line with
results from Bogani et al. who compared the type of sur-
gical approach for gynecological malignancies during the
years 2000–2003 with 2008–2011 and showed a compar-
able increase from 10 to 82%. Yet, these data were from
a single center and included large numbers that might
Table 1 Patient and tumor characteristics in relation to the type
of performed surgical procedure
Treatment characteristics
of all included patients
Total,
n = 556
LH,
n = 248
AH,
n = 308
p value
Age in years (mean, SD) 65.8 (9.6) 65.3 (9.8) 66.4 (9.4) 0.166
BMI (mean, SD) 29.6 (6.7) 29.8 (7.0) 29.3 (6.3) 0.429
Parity (mean, SD) 2.0 (1.4) 2.03 (1.4) 2.02 (1.3) 0.909
Previous abdominal
surgery
184 80 104 0.585
Comorbidity
Hypertension 178 77 101 0.582
Type II diabetes 83 30 53 0.093
FIGO stage 0.364
IA 336 158 178
IB 195 80 115
II 25 10 15
Histology 0.002
Endometrioid 502 231 271
Non-endometrioid
Serous 28 15 13
Clear cell 8 2 6
Carcinosarcoma 15 0 15
Stromal cell
sarcoma
3 0 3
Tumor grade 0.000
1 279 151 128
2 175 63 112
3 102 34 68
Treatment
Hysterectomy
and BSO
556 305 241 0.196
Additional staging/
lymphadenectomy
80 10 70 0.000
Conversion to
laparotomy
19 19 –
Duration of surgery,
min (mean, SD)
101 (41.9) 116 (39.3) 90 (40.4) 0.204
Complications
During surgery 26 19 7 0.004
After surgery 30 6 24 0.005
LH laparoscopic hysterectomy, AH abdominal hysterectomy
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explain a faster increase in implementation [17]. In com-
parison, the implementation of LH in the Netherlands
was relatively late when compared to that in other
countries, possibly due to the lack of centralization of
EC treatment resulting in many hospitals treating
small numbers [23]. Implementation in the Netherlands
might have been facilitated by the Dutch RCT, published
in 2010 [7].
The observed conversion rate changed over time and
was 6.9% in the last year of our study, quite in line with
the previous Dutch RCT that reported conversion rates
of 10.8%, but higher than the reported 2.4% in the LACE
trial [6, 7]. Even in 2015, this number is still relatively
high. Possible explanations are as follows: (1) variations
in the time of the start of LH between hospitals that
may not have reached the optimal surgical performance
at the time of analysis, (2) relatively small numbers per
hospital, and (3) a substantial proportion of obese pa-
tients (40.6%), since these are associated with increased
conversion rate [23, 24]. The overall comparable compli-
cation rates support our assumption that laparoscopic
surgeons in the GOCS region were sufficiently trained to
perform a LH. The absence of a decrease in the rate of
complications with the implementation of LH during the
10-year period can be explained by the fact that more
surgeons started to perform LH for endometrial cancer,
Fig. 2 Description of the proportion of surgical procedures (TLH, LAVH, or AH) in the years 2006, 2009, 2012, and 2015
Fig. 3 Mean duration of surgery in relation to the annual number of operated endometrial cancer patients
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each going through their individual learning curve. Ana-
lyses of an overall learning curve are thus a mixture of
several individual learning curves. The observed trend
towards an increased duration of surgery with less LH
cases per year suggests that surgical volume might be
relevant. However, since surgeons that perform LH of
endometrial cancer also perform LH for benign indica-
tions, these numbers should be included for a proper
analysis. The observation that the introduction of a TLH
was frequently preceded by a LAVH approach may
illustrate a step-wise adaptation of laparoscopic surgery.
Although we hypothesized, according to previous find-
ings, that patient-related factors such as BMI and previ-
ous abdominal surgery were predictive for the type of
surgical approach, we could not confirm this in our
study [24, 25]. In our study cohort, 72.6% of the patients
were overweight, with 40.6% being obese. The Dutch
RCT was conducted between 2007 and 2009, and train-
ing of the surgical team including the anesthesiologist
may have improved in recent years, resulting in reduced
conversion rate. Interestingly, the type of hospital was
related to the implementation of a laparoscopic ap-
proach. In 2015, all hospitals had implemented the LH,
but implementation was faster in teaching hospitals
compared to that in non-teaching hospitals. This is in
line with the study of Pijnenborg and ter Haar who
demonstrated the important contribution of residents in
teaching hospitals in the implementation of LH in clin-
ical practice [12]. We did not observe a relation between
the age or gender of surgeon and the type of primary
surgical approach in line with previous data [13, 14].
The safety of laparoscopy in the treatment of EC is
established in eight RCTs that included mainly early-
stage, low-grade EC [11]. There is strong evidence for
the role of laparoscopy in the management of low-grade
EC, yet for high-grade EC, data are still limited. In a
recently published study, it was shown that LH and
laparoscopic lymph node dissection were equally safe
when compared to open procedures in high-grade EC
[26]. Although numbers are relatively small, these data
illustrate the shift of the indication towards the laparo-
scopic approach in high-grade EC treatment. This is sup-
ported by a follow-up date of the Gynecologic Oncology
Group (GOG) LAP2 trial, which demonstrated that the
outcome of patients with high-risk histology, including
grade 3 endometrioid-type, serous, and clear cell carcino-
sarcoma, was not related to the type of surgical approach
[27]. In our study cohort, only 10 EC patients underwent
a LH with lymphadenectomy, since surgical staging was
implemented from 2015 onward. Yet, since numbers of
high-grade EC with laparoscopic surgery are limited, there
is still a need to continue monitoring whether a laparo-
scopic approach can be extended to high-grade EC pa-
tients. This switch from open to laparoscopic surgery has
great impact on the costs for healthcare. Even robotic-
assisted laparoscopic hysterectomy was shown to be 17%
cheaper when compared to AH, mainly due to a shorter
hospital stay [28]. This benefit may be even more when
conventional laparoscopic hysterectomy is performed and
dependent on the use of expensive disposable supplies
[29]. Whether advanced-stage EC can be treated by a
minimal invasive procedure equally safe has not been
studied so far.
This study has some limitations that need to be ad-
dressed. The surgical treatment of EC in the Netherlands
is not centralized, and consequently, the current data
reflect the clinical practice in one clinical oncology net-
work in the Netherlands [23]. Since 2015, the surgical
approach for EC is documented in the Netherlands
Cancer Registry, demonstrating that 79% (66–83%) of
the patients in 2015 with early-stage, low-grade EC were
operated by a LH (data not shown). Based on our find-
ings, we recommend to add the conversion rate and
BMI to this Netherlands Cancer Registry database to
monitor these in relation to annual cases in order to
further improve the quality of care. Both the years of
experience of individual surgeons with laparoscopic
hysterectomy for benign indication and the experience
of the surgical team have not been taken into account,
while this may have influenced our data.
Conclusions
In conclusion, LH has been well implemented in the sur-
gical treatment of early-stage EC in a clinical oncology
network in the Netherlands. Currently, 85% of the early-
stage EC patients are operated by LH, mainly patients
with low-grade tumor. Additional monitoring of conver-
sion and complication rates might contribute to im-
proved quality of care in the shift towards a laparoscopic
approach for the treatment of EC.
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